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Background: Korean ginseng is an ethnopharmacologically valuable herbal plant with various biological
properties including anticancer, antiatherosclerosis, antidiabetic, and anti-inﬂammatory activities. Since
there is currently no drug or therapeutic remedy derived from Korean ginseng, we developed a ginse-
noside-enriched fraction (AP-SF) for prevention of various inﬂammatory symptoms.
Methods: The anti-inﬂammatory efﬁcacy of AP-SF was tested under in vitro inﬂammatory conditions
including nitric oxide (NO) production and inﬂammatory gene expression. The molecular events of in-
ﬂammatory responses were explored by immunoblot analysis.
Results: AP-SF led to a signiﬁcant suppression of NO production compared with a conventional Korean
ginseng saponin fraction, induced by both lipopolysaccharide and zymosan A. Interestingly, AP-SF
strongly downregulated the mRNA levels of genes for inducible NO synthase, tumor necrosis factor-a,
and cyclooxygenase) without affecting cell viability. In agreement with these observations, AP-SF blocked
the nuclear translocation of c-Jun at 2 h and also reduced phosphorylation of p38, c-Jun N-terminal
kinase, and TAK-1, all of which are important for c-Jun translocation.
Conclusion: Our results suggest that AP-SF inhibits activation of c-Jun-dependent inﬂammatory events.
Thus, AP-SF may be useful as a novel anti-inﬂammatory remedy.
Copyright  2014, The Korean Society of Ginseng, Published by Elsevier. All rights reserved.1. Introduction
There is an increasing appreciation for the role of sustained
inﬂammation in the development of a number of serious diseases
such as cancer, diabetes, atherosclerosis, and skin disorders [1e3].
As such, many studies have focused on understanding inﬂamma-
tory processes and their role in disease progression [4]. Inﬂam-
matory responses are primarily mediated by innate immune cells
such as macrophages, dendritic cells, and Langerhans skin cells [5].
In particular, these cells play a critical role in protecting the body
from various infectious conditions. Under such conditions, these
cells produce a number of inﬂammatory mediators such as nitric
oxide (NO) and prostaglandin E2, as well as soluble factors such asgineering, Sungkyunkwan Universi
nstitute, AmorePaciﬁc R&D Center,
hin), jaecho@skku.edu (J.Y. Cho).
erms of the Creative Commons At
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e Korean Society of Ginseng, Publcytokines [e.g., tumor necrosis factor (TNF)-a] and chemokines
[6,7]. Secretion of these molecules requires a complicated signaling
cascade triggered by an interaction between surface receptors (e.g.,
toll-like receptors) in macrophages and ligands [e.g., lipopolysac-
charide (LPS), zymosan A (ZyM A), and polynucleotides] derived
from bacteria, fungi, and viruses [8]. The resulting biochemical in-
teractions amplify cellular signaling cascades managed by mitogen
activated protein kinases (p38, ERK, and c-Jun N-terminal kinase
[JNK]) and protein tyrosine kinases (Src and Syk) to induce trans-
location of transcription factors including nuclear factor (NF)-kB
(p50 and p65), activator protein, c-Fos, c-Jun, and activating tran-
scription factor 2, and interferon regulatory transcription factor
in order to increase transcriptional levels of inﬂammatory genesty, 2066 Seobu-ro, Suwon 440-746, Korea.
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J Ginseng Res 2015;39:155e161156[9e11]. Due to the pathophysiological action of inﬂammation in
humans, there is a need to develop safe and effective drugs to
attenuate inﬂammatory responses by targeting various biochem-
ical processes.
Korean ginseng (KG, a root of Panax ginsengMeyer, Araliaceae) is
a representative herbal plant ethnopharmacologically prescribed in
Korea [12,13]. The major active components of KG are well known,
comprising protopanaxadiol-type and protopanaxatriol-type gin-
senosides and acid polysaccharides [14,15]. These components
contribute to various pharmacological activities of ginseng such as
modulation of immune responses, normalization of brain functions,
increased activity of the antioxidative system, and attenuation of
skin troubles [15,16]. As mentioned above, the role of ginseng as an
anti-inﬂammatory remedy has been also proposed by several re-
ports. Red ginseng saponin fractions enriched with proto-
panaxadiol-type saponins were shown to suppress macrophage-
mediated inﬂammatory responses [17]. In addition, ginsenoside
(G)-Rb1, G-Rb2, and G-Rd were found to have striking anti-in-
ﬂammatory activities [18]. Nonetheless, no ginseng-derived com-
ponents have been developed as anti-inﬂammatory drugs,
although Artemisia asiatica, a representative Korean herb, has been
successfully developed as a specialized anti-gastritis drug. A critical
reason for considering Artemisia asiatica for drug development over
ginseng-derived components was because of its superior anti-in-
ﬂammatory activities. Indeed, ethanol extracts of Artemisia asiatica
(At-EE) strongly inhibit NO production, with an IC50 value of
44.1 mg/mL in LPS-treated RAW264.7 cells, which is signiﬁcantly
lower than those of ginseng-derived components [19]. By contrast,
water extracts of Korean Red Ginseng are nine times less potent
than At-EE [20]. Nevertheless, we ﬁrmly believe that ginseng-
derived components may be just as effective as At-EE when
considering their ability to modulate biochemical processes. Using
phytochemical preparation techniques, we developed concentrated
preparations of ginsenosides and then evaluated the anti-inﬂam-
matory strengths of these preparations on NO production, modu-
lation of inﬂammatory gene expression, and inﬂammatory
signaling cascades.
2. Materials and methods
2.1. Materials
Standard ginsenosides (G-Rg1, G-Re, G-Rb1, G-Rc, G-Rb2, and G-
Rd) were purchased from Ambo Institute (Daejeon, Korea). Nu-
Nitro- L-arginine methyl ester hydrochloride (L-NAME), (3-4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT),
and lipopolysaccharide (LPS, Escherichia coli 0111:B4) were pur-
chased from Sigma Chemical Co. (St Louis, MO, USA). RAW264.7
cells, a BALB/c-derivedmurinemacrophage cell line (ATCC No.: TIB-
71), were obtained from American Tissue Culture Collection (ATCC,
Rockville, MD, USA). Fetal bovine serum and RPMI1640 were pur-
chased from GIBCO (Grand Island, NY, USA), and phospho-speciﬁc
or total antibodies to c-Jun, c-Fos, ERK, p38, JNK, MKK3/6, TAK1,
lamin A/C, and b-actinwere purchased from Cell Signaling (Beverly,
MA, USA). All other chemicals were purchased from Sigma Chem-
ical Co.
2.2. Preparation of a ginsenoside-enriched fraction (AP-SF)
Dried and crushed roots of Panax ginseng (300 g) were extracted
in 70% aqueous methanol at room temperature (25C) for 2 d. The
extracts were concentrated under reduced pressure at 40C and
then partitioned between petroleum ether, ethyl acetate, and n-
butanol. The n-butanol fractions were further concentrated under
reduced pressure at 40C. The resulting residues were subjected toa HP-20 resin column and eluted with gradient aqueous methanol
(0%, 30%, and 100%, successively). Solvent was removed from the
100% methanol fractions and analyzed by high performance liquid
chromatography (HPLC). As a control, a Korean ginseng saponin
fraction (KG-SF) was prepared by concentration of a 70% aqueous
methanol extract.
2.3. HPLC analysis
HPLC analysis of ginsenosides in the prepared AP-SF and KG-SF
was carried out on a Waters HPLC system equipped with a UV
detector (Waters 2487; Waters, Milford, MA, USA), as reported
previously [21,22]. Separations were performed on a Sun ﬁre C18
column (3.5 mm, 4.6 mm  150 mm; Waters). The elution condi-
tions were as follows: solvent A, water; solvent B, acetonitrile;
gradient, 0e22min (18% B), 22e32min (18e30% B), and 32e60min
(30e50% B). The ﬂow rate was 1 mL/min, with detection at wave-
length 203 nm. A total of 20 mL of AP-SF or KG-SF solutions was
injected, and peaks were identiﬁed by comparing retention times
with those of reference ginsenosides.
2.4. AP-SF and KG-SF treatments
Stock solutions (10mg/mL) of AP-SF and KG-SF were prepared in
dimethylsulfoxide (DMSO) and diluted to 0e100 mg/mL with media
for in vitro cellular assays.
2.5. Cell culture
RAW 264.7 cells were cultured in RPMI 1640 medium supple-
mented with 10% heat-inactivated fetal bovine serum, glutamine,
and antibiotics (penicillin and streptomycin) at 37C in a 5% CO2
atmosphere. For experiments, cells were detached with a cell
scraper. Under the cell density conditions used in experiments
(2  106 cells/mL), the proportion of dead cells was < 1% according
to Trypan blue dye exclusion tests.
2.6. NO production
After preincubation for 18 h, RAW264.7 cells (1  106 cells/mL)
were pretreated with AP-SF or KG-SF (0e100 mg/mL) or a standard
compound (L-NAME) and incubated with LPS or ZyM A (1 mg/mL)
for 24 h. The inhibitory effects of these components on NO pro-
duction were determined by analyzing NO level quantiﬁed with
Griess reagent, as described previously [23,24].
2.7. Cell viability test
After preincubation for 18 h, AP-SF or KG-SF (0e100 mg/mL) was
added to RAW264.7 cells (1 106 cells/mL), followed by incubation
for 24 h. The cytotoxic effects of AP-SF or KG-SF were evaluated by
MTT assay, as described previously [25,26].
2.8. mRNA analysis by reverse transcriptaseepolymerase chain
reaction
To evaluate cytokine mRNA expression levels, RAW264.7 cells
were pretreated with AP-SF (0e50 mg/mL) for 1 h and incubated
with LPS (1 mg/mL) or ZyM A (400 mg/mL) for 6 h. Total RNA was
isolated with TRIzol Reagent (Gibco BRL) according to the manu-
facturer’s instructions and stored at 70C until use. Total RNA
from LPS- or ZyM A-treated RAW264.7 cells was prepared by
adding TRIzol Reagent (Gibco BRL), as per the manufacturer’s
protocol. Semiquantitative reverse transcriptaseepolymerase chain
reaction reactions were conducted using MuLV reverse
Table 1
Primers used for reverse transcriptaseepolymerase chain reaction
Gene name Sequence (50e30)
iNOS F CCCTTCCGAAGTTTCTGGCAGCAG
R GGCTGTCAGAGCCTCGTGGCTTTGG
COX-2 F CACTACATCCTGACCCACTT
R ATGCTCCTGCTTGAGTATGT
TNF-a F TGCCTATGTCTCAGCCTCTTC
R GAGGCCATTTGGGAACTTCT
GAPDH F CACTCACGGCAAATTCAACGGCA
R GACTCCACGACATACTCAGCAC
COX-2, cyclooxygenase-2; GAPDH, glyceraldehyde 3-phosphate dehydrogenase;
iNOS, inducible NO synthase; TNF-a, tumor necrosis factor-a
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Fig. 1. Cell viability and phytochemical proﬁle of AP-SF. (A) The viability of RAW264.7 cells t
by MTT assay. (B) Phytochemical characteristics of ginsenosides in AP-SF or KG-SF were ana
HPLC, high performance liquid chromatography; KG, Korean ginseng; MTT, (3-4,5-dimethyl
K.-S. Baek et al / AP-SF, a potent ginseng fraction 157transcriptase as described previously [27]. The primers (Bioneer,
Daejeon, Korea) described in Table 1 for inducible NO synthase
(iNOS), cyclooxygenase (COX)-2, TNF-a, and glyceraldehyde 3-
phosphate dehydrogenase detection were used as previously re-
ported [28].
2.9. Preparation of total lysates and nuclear extracts for
immunoblotting analysis
RAW264.7 cells (5  106 cells/mL) were washed three times in
cold PBS with 1 mM sodium orthovanadate and then lysed using a
sonicator (Thermo Fisher Scientiﬁc, Waltham, MA, USA) or a Tis-
suemizer (Qiagen, Germantown, MD, USA) in lysis buffer [29] for
30minwith rotation at 4C. Lysates were clariﬁed by centrifugation
at 16,000  g for 10 min at 4C and stored at 20C until use.KG-SF
AP-SF
5 50 100
/mL) 
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 time (min)
             40                        50                    60
AP-SF
KG-SF
  G-Rc G-Rb2  G-Rd
reated with either AP-SF or KG-SF in the absence of lipopolysaccharide was determined
lyzed by HPLC. (C) The ginsenoside contents of AP-SF and KG-SF. AP, activator protein;
thiazol-2-yl)-2,5-diphenyltetrazolium bromide; SF, saponin fraction.
020
40
60
80
100
120 KG-SF
AP-SF
N
O
 p
ro
du
ct
io
n
(%
 o
f c
on
tr
ol
)
LPS (1 g/mL)
Conc. ( g/mL)
A
**
** **
*
μ
μ
0
20
40
60
80
100
120 KG-SF
AP-SF
N
O
 p
ro
du
ct
io
n
(%
 o
f c
on
tr
ol
)
ZyM A (400 
Conc. (
B
**
**
**
*
**
**
**
**
μg/mL)
μg/mL)
C
0
20
40
60
80
100
120
N
O
 p
ro
du
ct
io
n 
(%
 o
f c
on
tr
ol
)
0              250            500            750
Conc. (μM)
*
**
*
Fig. 2. Effect of AP-SF on NO production in activated RAW264.7 cells. (A, B, and C)
Levels of NO were determined from culture supernatants of RAW264.7 cells treated
with (A and C) LPS (1 mg/mL) or (B) ZyM A (400 mg/mL) in the presence or absence of
(A) AP-SF or KG-SF or (C) L-NAME for 24 h. *p < 0.05 and **p < 0.01 compared to the
control. AP, activator protein; KG, Korean ginseng; L-NAME, Nu-Nitro-L-arginine methyl
ester hydrochloride; LPS, lipopolysaccharide; NO, nitric oxide; SF, saponin fraction;
ZyM A, zymosan A.
Table 2
Inhibitory activity of AP-SF and KG-SF on nitric oxide production
Stimulus IC50 value (mg/mL)
AP-SF KG-SF
Lipopolysaccharide 45.1  0.7 82.6  2.4
Zymosan A 15.3  1.0 23.5  0.2
J Ginseng Res 2015;39:155e161158Nuclear fractions were prepared with RAW264.7 cell-derived ly-
sates in a three-step procedure [30]. After treatment, cells were
collected with a rubber policeman, washed once with PBS, and
lysed in 500 mL of lysis buffer [31] on ice for 4 min. Lysates were
centrifuged at 19,326  g for 1 min in a microcentrifuge. The
resulting pellet (nuclear fraction) was washed once in wash buffer(lysis buffer without Nonidet P-40) and then treated with extrac-
tion buffer (lysis buffer containing 500 mM KCl and 10% glycerol).
The nuclei/extraction buffer mixture was frozen at 80C, thawed
on ice, and centrifuged at 19,326  g for 5 min. The resulting su-
pernatant was collected as the nuclear extract. Soluble cell lysates
(30 mg/lane) were subjected to immunoblotting. Levels of total or
phosphorylated c-Jun, c-Fos, ERK, p38, JNK, MKK3/6, lamin A/C, and
b-actin were visualized as previously described [32].
2.10. Statistical analysis
In vitro experiments in this paper are presented as the
mean  standard error of three different experiments each per-
formed using four samples. For statistical comparisons, results
were analyzed using analysis of variancewith Scheffe’s post hoc and
KruskaleWallis/ManneWhitney tests. A p value < 0.05 was
considered statistically signiﬁcant. All statistical tests were per-
formed using SPSS (SPSS Inc., Chicago, IL, USA).
3. Results and discussion
Inﬂammation is well known to cause various diseases such as
cancer, diabetes, and atherosclerosis [33]. In addition, inﬂamma-
tory conditions of the skin and hair leading to skin troubles such as
wrinkling and hair loss can be treated with anti-inﬂammatory
biomaterials applied to cosmetic preparations for the purpose of
antiaging, skin-protection, and hair-loss prevention [34]. Recently,
our group developed a new ginsenoside-enriched preparation (AP-
SF) with a higher ginsenoside content and reported that this frac-
tion exhibits increased antioxidative and hair growth-stimulating
activities. In this study, we aimed to determine whether AP-SF is
able to strongly suppress various in vitro inﬂammatory responses.
First, in order to identify a noncytotoxic dose range of AP-SF,
RAW264.7 cell viability was analyzed after exposure to AP-SF. As
shown in Fig. 1A, the AP-SF fraction did not show any signiﬁcant
suppression of cell viability up to 100 mg/mL. Similarly, cell viability
was not signiﬁcantly affected by exposure to KG-SF. To conﬁrm the
phytochemical proﬁle of AP-SF, its speciﬁc ginsenoside contents
were evaluated. As shown in Fig. 1B, G-Rg1, G-Re, G-Rb1, G-Rc, G-
Rb2, and G-Rd were detected as the major ginsenosides in AP-SF.
Further, the levels of diol-type ginsenosides in AP-SF were signiﬁ-
cantly, up to 50-fold, higher than those of KG-SF.
We next examined the immunomodulatory effects of AP-SF by
comparison with KG-SF. To this end, we employed in vitro anti-in-
ﬂammatory assays, as we have shown previously that Korean Red
Ginseng water extract (KRG-WE) containing saponin fractions and
protopanaxadiol-type saponin fractions exhibit anti-inﬂammatory
effects in LPS-treated RAW264.7 cells [20]. As expected, KG-SF
dose-dependently inhibited NO production in LPS-treated
RAW264.7 cells (Fig. 2A). Interestingly, AP-SF suppressed NO pro-
duction by two-fold compared to KG-SF at the same concentration.
Consistent with this observation, 50 mg/mL of AP-SF produced a
similar degree of NO inhibition as KG-SF at 100 mg/mL (Fig. 2A). L-
NAME inhibited LPS-induced NO production in a dose-dependent
manner (Fig. 2C), as reported previously [19], indicating that our
experimental conditions werewell established. Furthermore, while
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K.-S. Baek et al / AP-SF, a potent ginseng fraction 159KG-SF very strongly suppressed NO release induced by ZyM A, a
RAW264.7 glucanwith repeating glucose units connected by b-1,3-
glycosidic linkages [35], AP-SF produced more potent suppression
(Fig. 2B) according to IC50 values (Table 2). Together, these data
indicate that Korean ginseng-derived saponin components strongly
block fungus-derived inﬂammatory responses.
It has been reported that fungus-derived immunogens can cause
cellular and tissue damage, as well as various inﬂammatory dis-
eases [36]. Candidiasis, codermatophytes, aspergillosis, and pneu-
monia are representative diseases caused by fungal infections
[37,38]. In addition, various skin troubles as well as fungal-initiated
hair loss can be caused by fungal infections of the skin and hair [39].
Considering the prevalence of these conditions and the strong
inhibitory potential of AP-SF against inﬂammatory responses
induced by the fungus-derived immunogen, Zym A (Fig. 2B), we
hypothesized that AP-SF might be useful for treating fungal-
derived dermatitis and infectious diseases as well as fungal-
induced hair loss.
Because AP-SF exhibited strong NO inhibitory activity in acti-
vated RAW264.7 cells, we further characterized its anti-inﬂam-
matory effects by measuring mRNA levels of inﬂammatory genes.
As shown in Fig. 3A, treatment with AP-SF strongly decreased
mRNA levels of iNOS, COX-2, and TNF-a at 25 mg/mL and 50 mg/mL.
Similar to the NO inhibitory activity observed in ZyM A-treated
RAW264.7 cells, AP-SF strongly inhibited mRNA expression of in-
ﬂammatory genes in cells treated with ZyM A (Fig. 3B). These re-
sults clearly indicate that AP-SF-mediated inhibition of NO
production is facilitated at the level of transcription. Similar anti-
inﬂammatory patterns were also conﬁrmed by treatment of KRG-
WE following exposure to LPS [20]. It has been also reported that
compound K is able to reduce ZyM A-induced cytokine genep-ERK
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gnaling pathways. (A) The total protein levels of c-Fos and c-Jun were identiﬁed by
d D) RAW264.7 cells were incubated with LPS (1 mg/mL) in the presence or absence of
K1, IRAK1, and IRAK4 in whole lysates were determined by immunoblotting analysis.
J Ginseng Res 2015;39:155e161160expression [40]. These results suggest that ginseng-derived com-
ponents are capable of modulating inﬂammatory responses by
suppressing transcriptional activation of inﬂammatory genes.
Because AP-SF was shown to block the transcriptional activation
of inﬂammatory genes, we next aimed to determine its targeted
transcription factors. Since it was previously reported that the
translocation of activator protein-1 is suppressed by KRG-WE and
protopanaxadiol type saponin fraction (PPD-SF) [20], we measured
levels of c-Jun and c-Fos following treatment with AP-SF. As shown
in Fig. 4A, the level of c-Jun in nuclear fractions at 120 min was
remarkably reduced by AP-SF (50 mg/mL). In agreement with this
result, the phosphorylation of p38, an upstream signaling enzyme
that activates c-Jun [41], was also suppressed by AP-SF at 30 min
and 45 min (Fig. 4B), indicating that the inhibition of p38 phos-
phorylation at these timesmight contribute to the suppression of c-
Jun translocation. Interestingly, the phosphorylation of mitogen-
activated protein kinase kinase 3/6 (MKK3/6), an upstream enzyme
that phosphorylates p38 [42], at 30 min and 45 min was also
inhibited by AP-SF (Fig. 4C), implying that p38 is not directly tar-
geted by this extract. Indeed, the phosphorylation of transforming
growth factor-betaeactivated kinase 1 (TAK1), an upstream kinase
that phosphorylates MKK3/6 [42], was also remarkably suppressed
by AP-SF at 2 min, 3 min, and 5 min. These results clearly suggest
that AP-SF is able to modulate c-Jun translocation by suppressing
TAK1/MKK3/6-related signaling.
The signiﬁcance of the TAK1-mediated p38/c-Jun activation
pathway in inﬂammatory responses has beenwidely demonstrated
using pharmacological and molecular biological approaches [43].
Speciﬁcally, JLU1124 and SB203580, inhibitors of p38, are able to
block LPS-induced production of NO, IL-6, and TNF-a and decrease
the expression of iNOS and COX-2 in RAW264.7 macrophages [44].
In addition, toll-like receptor 2-mediated autoimmune inﬂamma-
tion in multiple sclerosis and experimental autoimmune enceph-
alomyelitis is known to involve the TAK1 axis [45]. The isoform of
p38 is regarded as a novel molecular target to attenuateFig. 5. Putative inhibitory pathway of the AP-SF-mediated anti-inﬂammatory
response. TLR4: toll like receptor 4, MyD88: myeloid differentiation primary response
protein-88, AP-1: activator protein-1.inﬂammatory responses, and several pyrindinyl imidazole com-
pounds have been developed and strongly inhibit p38a by dimin-
ishing levels of TNF-a and IL-1 [46]. Considering these ﬁndings, our
observation that AP-SF was able to inhibit the TAK1/p38/c-Jun
regulatory loop as summarized in Fig. 5 suggests its potential use as
an anti-inﬂammatory remedy. Importantly, there are currently no
preparations or single compounds derived from ginseng or red
ginseng that exhibit therapeutic efﬁcacy. Our data, however, have
encouraged us to consider whether this preparation can be devel-
oped as a special functional food or therapeutic drug. Following
additional veriﬁcation of the immunopharmacological activity of
AP-SF, it is our intention to evaluate this preparation using in vivo
inﬂammation models.Conﬂicts of interest
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